Open AccessA plasma proteogenomic signature for fibromuscular dysplasia
Author(s) -
Jeffrey W. Olin,
Antonio F Di Narzo,
Valentina d’Escamard,
Daniella KadianDodov,
Haoxiang Cheng,
Adrien Georges,
Annette King,
A. Taylor Thomas,
Temo Barwari,
Katherine C. Michelis,
Rihab Bouchareb,
Emir Bander,
Anelechi Anyanwu,
Paul Stelzer,
Farzan Filsoufi,
Sander Florman,
Mete Civelek,
Stéphanie Debette,
Xavier Jeunemaı̂tre,
Johan Björkegren,
Manuel Mayr,
Nabila Bouatia-Naji,
Ke Hao,
Jason C. Kovacic
Publication year - 2019
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1093/cvr/cvz219
Subject(s) - cohort , fibromuscular dysplasia , medicine , proteomics , pathology , blood proteins , bioinformatics , biology , genetics , gene , renal artery , kidney
Fibromuscular dysplasia (FMD) is a poorly understood disease that predominantly affects women during middle-life, with features that include stenosis, aneurysm, and dissection of medium-large arteries. Recently, plasma proteomics has emerged as an important means to understand cardiovascular diseases. Our objectives were: (i) to characterize plasma proteins and determine if any exhibit differential abundance in FMD subjects vs. matched healthy controls and (ii) to leverage these protein data to conduct systems analyses to provide biologic insights on FMD, and explore if this could be developed into a blood-based FMD test.